Strategic funding EpiEndo has recently secured convertible bond financing totaling approximately €9 million with a €5.84 million new tranche in January 2026, signaling investor appetite and potential for collaboration on further financing rounds or co-development deals.

Pipeline potential The lead asset glasmacinal (EP395) is an orally available macrolide with reduced antimicrobial resistance potential, targeting chronic respiratory diseases and barrier impairment. This positions EpiEndo for partnerships in inflammatory and respiratory indications, including potential investigator-driven studies or licensing discussions.

Academic collaboration Recent collaboration with Lund University and formal Scientific Advisory Board appointments indicate a strong emphasis on translational research and data generation, offering opportunities for research collaborations, co-development, and visibility in academic-led trials.

Key events Upcoming and recent appearances at major meetings such as the British Thoracic Society Winter Meeting provide windows to present data, engage KOLs, and initiate sponsor or co-development conversations with pharma and biotech partners focused on airway, GI, and skin barrier disorders.

Global focus With operations split between Iceland and international partners and a clinical-stage profile, EpiEndo presents a ready platform for global partnerships in regulatory-lean pathways, potential distributor agreements, and early-access initiatives in jurisdictions open to novel barrier-enhancing anti-inflammatories.